

BridgeBio Pharma, Inc. (BBIO)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001743881

BridgeBio Pharma, Inc. BBIO; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 11.1; sampling error 2.5 points; lower is stronger
Rank	42 of 371
Profitability	A/B percentile 18.2
Solvency	D percentile 63.3
Growth and financing	A/B percentile 21.8
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$936.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 24, 2026 227 days before the rescans; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$64.99 2026-10-08; market equity \$12.7B
Price used in grade	None




A, the bull

strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D/E from Mar 21, 2024, D from Feb 21, 2025, C/D from Apr 21, 2025, A from Mar 21, 2026

Letter at every rescanscan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026


BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been

treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the "FDA") approval for three products.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 18.2						
Gross profitability		51.4%	32.2%	22.4	372	2025-12-31
Return on invested capital		not computable	9.3%			prior invested-capital observation is 2192 days earlier
Accruals ratio		(30.9%)	(6.6%)	14.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 4
Solvency, sleeve percentile 63.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(14.22)	(0.31)	68.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.77x	2.96x	58.1	839	2025-12-31
Growth and financing, sleeve percentile 21.8						
Revenue growth, three-year compound		86.3%	10.0%	6.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		14.5%	2.1%	26.7	704	2025-12-31
Net share issuance, one year		1.9%	2.5%	31.9	634	2026-02-12



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
37	Viemed Healthcare, Inc. (VMD)	9.7	A	
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet
39	TransMedics Group, Inc. (TMDX)	10.3	A	
40	TG Therapeutics, Inc. (TGTX)	10.5	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO) <	11.1	A	
43	PRO DEX Inc. (PDEX)	11.4	A	
44	Sanara MedTech Inc. (SMTI)	11.6	A	
45	Orthopediatrics Corp. (KIDS)	11.9	A	
46	Idexx Laboratories Inc. (IDXX)	12.2	A	
47	Procept BioRobotics Corp. (PRCT)	12.4	A	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	47.5%	8.0%	75
Distance from 52-week high	(27.9%)	(31.4%)	55
EBIT to enterprise value	(3.6%)	(1.5%)	45
Free cash flow yield	(3.5%)	(1.0%)	44
Book value to price	(0.20)	0.28	6
Sales to price	0.04	0.31	14
Composite equity issuance, five years	27.2%	20.3%	55
Relative strength against the sector, log excess return	0.18	(0.14)	75

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$677.9M
Operating cash flow, four quarters	-\$434.4M

Months of runway	18.7
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$175.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$502.1M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
2	cost of revenue	us-gaap:CostOfRevenue	\$21.0M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
3	assets	us-gaap:Assets	\$936.0M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
4	operating income	us-gaap:OperatingIncomeLoss	-\$523.4M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$673.5M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$435,000	2025-12-31	2026-02-24	10-K	0001743881-26-000009
7	total debt	us-gaap:LongTermDebt	\$2.0B	2025-12-31	2026-02-24	10-K	0001743881-26-000009
8	book equity	us-gaap:StockholdersEquity	-\$2.1B	2025-12-31	2026-02-24	10-K	0001743881-26-000009
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$570.1M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
10	total debt	us-gaap:LongTermDebt	\$95.4M	2019-12-31	2020-03-03	10-K	0001564590-20-008260
11	book equity	us-gaap:StockholdersEquity	\$408.5M	2019-12-31	2021-02-25	10-K	0001564590-21-008969
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$363.8M	2019-12-31	2022-02-25	10-K	0000950170-22-002030
13	net income	us-gaap:ProfitLoss	-\$732.9M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$445.9M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
15	assets	us-gaap:Assets	\$919.3M	2024-12-31	2026-02-24	10-K	0001743881-26-000009
16	current assets	us-gaap:AssetsCurrent	\$797.7M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
17	current liabilities	us-gaap:LiabilitiesCurrent	\$288.0M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$3.8B	2025-12-31	2026-02-24	10-K	0001743881-26-000009
19	liabilities	us-gaap:Liabilities	\$3.0B	2025-12-31	2026-02-24	10-K	0001743881-26-000009
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$5.4M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
21	operating income	us-gaap:OperatingIncomeLoss	-\$607.4M	2023-12-31	2026-02-24	10-K	0001743881-26-000009
22	interest expense	us-gaap:InterestExpense	\$81.3M	2023-12-31	2024-02-22	10-K	0000950170-24-018811
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$221.9M	2024-12-31	2026-02-24	10-K	0001743881-26-000009
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.3M	2023-12-31	2026-02-24	10-K	0001743881-26-000009
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$77.6M	2022-12-31	2025-02-20	10-K	0000950170-25-024119
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.1M	2025-12-31	2026-02-24	10-K	0001743881-26-000009
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$520.7M	2024-12-31	2026-02-24	10-K	0001743881-26-000009
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$933,000	2024-12-31	2026-02-24	10-K	0001743881-26-000009
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$527.7M	2023-12-31	2026-02-24	10-K	0001743881-26-000009
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.3M	2023-12-31	2026-02-24	10-K	0001743881-26-000009
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$419.5M	2022-12-31	2025-02-20	10-K	0000950170-25-024119
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.8M	2022-12-31	2025-02-20	10-K	0000950170-25-024119
33	current assets	us-gaap:AssetsCurrent	\$720.7M	2024-12-31	2026-02-24	10-K	0001743881-26-000009
34	current liabilities	us-gaap:LiabilitiesCurrent	\$154.4M	2024-12-31	2026-02-24	10-K	0001743881-26-000009
35	assets	us-gaap:Assets	\$546.4M	2023-12-31	2025-02-20	10-K	0000950170-25-024119
36	assets	us-gaap:Assets	\$623.0M	2022-12-31	2024-02-22	10-K	0000950170-24-018811
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	193,862,871	2026-02-12	2026-02-24	10-K	0001743881-26-000009
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	190,188,626	2025-02-13	2025-02-20	10-K	0000950170-25-024119